Epsilen Bio is a preclinical stage biotechnology company, located in Milan, Italy. The company was co-founded by Fondazione Telethon, Ospedale San Raffaele, Dr. Angelo Lombardo and Pr. Luigi Naldini, and backed by Sofinnova Partners.
The company aims at improving the health of patients suffering from medical conditions that derive from expression of altered or mutated genes, through the exploitation of an innovative technology of epigenetic silencing developed by its scientific founders at SR-Tiget.
Epsilen Bio’s objective is to translate this scientific innovation into transformative therapeutic approaches to address a variety of diseases with high unmet medical need.